66.04
1.41 (2.18%)
| Penutupan Terdahulu | 64.63 |
| Buka | 64.04 |
| Jumlah Dagangan | 768,948 |
| Purata Dagangan (3B) | 752,962 |
| Modal Pasaran | 4,751,513,600 |
| Harga / Jualan (P/S) | 120.55 |
| Harga / Buku (P/B) | 4.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -336.77% |
| EPS Cair (TTM) | -3.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 114.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.98% |
| Nisbah Semasa (MRQ) | 8.49 |
| Aliran Tunai Operasi (OCF TTM) | -234.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -136.32 M |
| Pulangan Atas Aset (ROA TTM) | -19.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Kymera Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.50% |
| % Dimiliki oleh Institusi | 104.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 90.00 (Guggenheim, 36.28%) | Beli |
| Median | 77.50 (17.35%) | |
| Rendah | 63.00 (Oppenheimer, -4.60%) | Beli |
| Purata | 76.20 (15.39%) | |
| Jumlah | 10 Beli | |
| Harga Purata @ Panggilan | 58.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 26 Nov 2025 | 80.00 (21.14%) | Beli | 67.86 |
| 30 Sep 2025 | 68.00 (2.97%) | Beli | 56.60 | |
| Barclays | 05 Nov 2025 | 70.00 (6.00%) | Beli | 59.89 |
| 17 Sep 2025 | 60.00 (-9.15%) | Beli | 48.12 | |
| HC Wainwright & Co. | 05 Nov 2025 | 84.00 (27.20%) | Beli | 59.89 |
| 18 Sep 2025 | 70.00 (6.00%) | Beli | 51.16 | |
| Wells Fargo | 05 Nov 2025 | 69.00 (4.48%) | Beli | 59.89 |
| Guggenheim | 03 Nov 2025 | 90.00 (36.28%) | Beli | 59.72 |
| BTIG | 22 Oct 2025 | 75.00 (13.57%) | Beli | 55.80 |
| Mizuho | 21 Oct 2025 | 81.00 (22.65%) | Beli | 58.32 |
| Citigroup | 17 Oct 2025 | 80.00 (21.14%) | Beli | 59.83 |
| Oppenheimer | 01 Oct 2025 | 63.00 (-4.60%) | Beli | 54.66 |
| RBC Capital | 16 Sep 2025 | 70.00 (6.00%) | Beli | 48.78 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |